期刊
PHARMACEUTICALS
卷 3, 期 7, 页码 2197-2212出版社
MDPI
DOI: 10.3390/ph3072197
关键词
cannabinoids; cannabidiol; ischemic stroke; neuroprotective effect
资金
- Ministry of Education, Culture, Sports, Science, and Technology of Japan [20590552]
- Advanced Materials Institute of Fukuoka University
- Grants-in-Aid for Scientific Research [20590552] Funding Source: KAKEN
Cannabis contains the psychoactive component delta(9)-tetrahydrocannabinol (delta(9)-THC), and the non-psychoactive components cannabidiol (CBD), cannabinol, and cannabigerol. It is well-known that delta(9)-THC and other cannabinoid CB1 receptor agonists are neuroprotective during global and focal ischemic injury. Additionally, delta(9)-THC also mediates psychological effects through the activation of the CB1 receptor in the central nervous system. In addition to the CB1 receptor agonists, cannabis also contains therapeutically active components which are CB1 receptor independent. Of the CB1 receptor-independent cannabis, the most important is CBD. In the past five years, an increasing number of publications have focused on the discovery of the anti-inflammatory, anti-oxidant, and neuroprotective effects of CBD. In particular, CBD exerts positive pharmacological effects in ischemic stroke and other chronic diseases, including Parkinson's disease, Alzheimer's disease, and rheumatoid arthritis. The cerebroprotective action of CBD is CB1 receptor-independent, long-lasting, and has potent anti-oxidant activity. Importantly, CBD use does not lead to tolerance. In this review, we will discuss the therapeutic possibility of CBD as a cerebroprotective agent, highlighting recent pharmacological advances, novel mechanisms, and therapeutic time window of CBD in ischemic stroke.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据